Intellia Therapeutics, Inc.NTLA

Healthcarediscovered
Neutral

ASignal's systematic analysis rates NTLA as Neutral. Intellia Therapeutics, Inc. has a market cap of $1.50B, a 0.0% net margin, and -9.5% year-over-year revenue growth.

Reflects the latest available analysis · analyzed Jul 25, 2026

The case on NTLA

Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.

Bull case
  • Strong financial health with low debt-to-equity ratio (0.13x)
  • High liquidity with current ratio of 6.10x and quick ratio of 5.04x
  • Substantial cash reserves of $375.99M providing runway for R&D
VS
Bear case
  • Negative MACD histogram suggesting continued downtrend
  • Negative operating cash flow of $-363.15M and free cash flow of $-235.23M
  • Operating margin at -668.07% reflecting significant operational losses
  • Revenue decline of 9.5% year-over-year
  • Negative return on equity (-56.34%) and return on assets (-30.14%)
  • Enterprise value to EBITDA at -2.93x indicating unprofitability

Key facts

Sector
Healthcare
Market cap
$1.50B
Gross margin
0.0%
Net margin
0.0%
Rev growth YoY
-9.5%
Price (Jul 25, 2026)
$10.73
Subscriber-only

See the full verdict on NTLA

ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.

How ASignal analyzes NTLA

Most investors never get a second opinion, let alone several. ASignal runs NTLA past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.

The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.

Intellia Therapeutics, Inc. (NTLA) Stock Analysis - ASignal rates it Neutral